| 000 | 01252 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250515024820.0 | ||
| 264 | 0 | _c20060525 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a1543-2165 | ||
| 024 | 7 |
_a10.5858/2006-130-669-IROAO _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLitzow, Mark R | |
| 245 | 0 | 0 |
_aImatinib resistance: obstacles and opportunities. _h[electronic resource] |
| 260 |
_bArchives of pathology & laboratory medicine _cMay 2006 |
||
| 300 |
_a669-79 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 773 | 0 |
_tArchives of pathology & laboratory medicine _gvol. 130 _gno. 5 _gp. 669-79 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5858/2006-130-669-IROAO _zAvailable from publisher's website |
| 999 |
_c16284566 _d16284566 |
||